Keyphrases
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
100%
Androgen Deprivation Therapy
100%
Systemic Chemotherapy
100%
Survival Benefit
80%
Docetaxel
80%
CHAARTED
60%
Prostate Cancer
20%
Randomized Trial
20%
Patient Characteristics
20%
Standard of Care
20%
Progression-free Survival
20%
Randomized Controlled Trial
20%
Statistical Power
20%
Androgen Ablation
20%
Statistical Significance
20%
Performance Status
20%
Extensive Disease
20%
Subgroup Analysis
20%
Low Sample Size
20%
Practice Recommendations
20%
Absolute Difference
20%
Evidence-based Recommendations
20%
Docetaxel Chemotherapy
20%
Low Volume Disease
20%
Chemohormonal Therapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Prostate Cancer
100%
Androgen
100%
Docetaxel
83%
Diseases
50%
Hormone Cancer Therapy
16%
Randomized Controlled Trial
16%
Progression Free Survival
16%
Medicine and Dentistry
Prostate Cancer
100%
Androgen Deprivation Therapy
83%
Docetaxel
83%
Diseases
50%
Hormone Therapy
16%
Progression Free Survival
16%
Subgroup Analysis
16%
Randomized Controlled Trial
16%
Patient Characteristics
16%
Arm
16%
Androgen
16%
Nursing and Health Professions
Prostate Cancer
100%
Androgen Deprivation Therapy
83%
Docetaxel
83%
Diseases
50%
Health Care Quality
16%
Sample Size
16%
Hormonal Therapy
16%
Progression Free Survival
16%
Outcome Variable
16%
Androgen
16%
Neuroscience
Androgen
100%
Prostate
100%
Docetaxel
83%
Randomized Controlled Trial
16%
Hormone Therapy
16%
Biochemistry, Genetics and Molecular Biology
Randomized Controlled Trial
100%
Progression Free Survival
100%
Sample Size
100%